Comparison of neoadjuvant single-agent treatment and dual-HER2 blockade for breast-conserving surgery conversion in HER2-positive breast cancer: a meta-analysis
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- Extent
-
1 Online-Ressource.
- Language
-
Englisch
- Bibliographic citation
-
Comparison of neoadjuvant single-agent treatment and dual-HER2 blockade for breast-conserving surgery conversion in HER2-positive breast cancer: a meta-analysis ; volume:24 ; number:1 ; day:18 ; month:10 ; year:2024 ; pages:1-8 ; date:12.2024
BMC cancer ; 24, Heft 1 (18.10.2024), 1-8, 12.2024
- Creator
-
Cui, Manlu
Fu, Juan
Li, Qiuyun
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1186/s12885-024-13052-5
- URN
-
urn:nbn:de:101:1-2501072129253.673914204321
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
15.08.2025, 7:29 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Cui, Manlu
- Fu, Juan
- Li, Qiuyun
- SpringerLink (Online service)
Other Objects (12)
PYK2 promotes HER2-positive breast cancer invasion
Comparison of tumors with HER2 overexpression versus HER2 amplification in HER2-positive breast cancer patients
Nanotechnology approaches to addressing HER2-positive breast cancer
How We Treat HER2-Positive Metastatic Breast Cancer
Is neoadjuvant chemotherapy necessary for T2N0-1M0 hormone receptor-positive/HER2-negative breast cancer patients undergoing breast-conserving surgery?
Synthetic lethality between HER2 and transaldolase in intrinsically resistant HER2-positive breast cancers
ASCO 2019: highlights in HER2-positive metastatic breast cancer
ASCO 2018: highlights in HER2-positive metastatic breast cancer
Differential response of HER2-positive breast cancer to anti-HER2 therapy based on HER2 protein expression level
HER2 amplification by next-generation sequencing to identify HER2-positive invasive breast cancer with negative HER2 immunohistochemistry
Breast diseases : breast-conserving therapy, non-invasive therapy, mastopathy
Radiotherapy refusal in breast cancer with breast-conserving surgery
PYK2 promotes HER2-positive breast cancer invasion
Comparison of tumors with HER2 overexpression versus HER2 amplification in HER2-positive breast cancer patients
Nanotechnology approaches to addressing HER2-positive breast cancer
How We Treat HER2-Positive Metastatic Breast Cancer
Is neoadjuvant chemotherapy necessary for T2N0-1M0 hormone receptor-positive/HER2-negative breast cancer patients undergoing breast-conserving surgery?
Synthetic lethality between HER2 and transaldolase in intrinsically resistant HER2-positive breast cancers
ASCO 2019: highlights in HER2-positive metastatic breast cancer
ASCO 2018: highlights in HER2-positive metastatic breast cancer
Differential response of HER2-positive breast cancer to anti-HER2 therapy based on HER2 protein expression level
HER2 amplification by next-generation sequencing to identify HER2-positive invasive breast cancer with negative HER2 immunohistochemistry
Breast diseases : breast-conserving therapy, non-invasive therapy, mastopathy
Radiotherapy refusal in breast cancer with breast-conserving surgery
PYK2 promotes HER2-positive breast cancer invasion
Comparison of tumors with HER2 overexpression versus HER2 amplification in HER2-positive breast cancer patients
Nanotechnology approaches to addressing HER2-positive breast cancer
How We Treat HER2-Positive Metastatic Breast Cancer
Is neoadjuvant chemotherapy necessary for T2N0-1M0 hormone receptor-positive/HER2-negative breast cancer patients undergoing breast-conserving surgery?
Synthetic lethality between HER2 and transaldolase in intrinsically resistant HER2-positive breast cancers
ASCO 2019: highlights in HER2-positive metastatic breast cancer
ASCO 2018: highlights in HER2-positive metastatic breast cancer
Differential response of HER2-positive breast cancer to anti-HER2 therapy based on HER2 protein expression level
HER2 amplification by next-generation sequencing to identify HER2-positive invasive breast cancer with negative HER2 immunohistochemistry
Breast diseases : breast-conserving therapy, non-invasive therapy, mastopathy